Skip to content
Study details
Enrolling now

Immunotherapy and Irreversible Electroporation for Advanced Pancreatic Cancer

University of Louisville
NCT IDNCT03080974ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

10

Study length

about 12 years

Ages

18+

Locations

1 site in KY

About this study

Researchers are testing whether irreversible electroporation, given together with Nivolumab, can help people with locally advanced pancreatic cancer. The trial will also look at how well this treatment works and if it causes any side effects.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Nivolumab
  • 2.Undergo Irreversible Electroporation
PhasePhase 2
DrugNivolumab
Routeinfusion
Primary goalSafety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low11%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

nivolumab (Immune checkpoint inhibitor; blocks PD-1 receptor on T cells)

Drug routes

infusion

Endpoints

Primary: Safety and Tolerability of Combination Irreversible Electroporation and Nivolumab Treatment

Secondary: Overall Survival, Progression Free Survival